A laboratory evaluation into the short activated partial thromboplastin time

Blood Coagulation and Fibrinolysis

Volumn 21, Issue 2, 2010, Pages 152-157

  Mina, Ashraf ^a   Favaloro, Emmanuel J ^a   Mohammed, Soma ^a   Koutts, Jerry ^a  

^a WESTMEAD HOSPITAL   (Australia)

Author keywords

Activated partial thromboplastin time (APTT); Coagulation factors; Fibrinogen; Phospholipids; Procoagulant status; Von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; COLLAGEN; FIBRINOGEN; PHOSPHOLIPID; PROCOAGULANT; VON WILLEBRAND FACTOR;

ARTICLE; CONTROLLED STUDY; HUMAN; HYPERCOAGULABILITY; LABORATORY TEST; NORMAL VALUE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN BINDING; SHORT PARTIAL THROMBOPLASTIN TIME; XACT ASSAY;

HUMANS; PARTIAL THROMBOPLASTIN TIME; PROSPECTIVE STUDIES; THROMBOPHILIA;

EID: 76449121792     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3283365770     Document Type: Article

References (26)

1. Lippi G, Favaloro EJ. Activated partial thromboplastin time: new tricks for an old dogma. Semin Thromb Hemost 2008; 34:604-611.
2. Korte W, Clarke S, Lefkowitz JB. Short activated partial thromboplastin times are related to increased thrombin generation and an increased risk for thromboembolism. Am J Clin Pathol 2000; 113:123-127.
3. Reiner JS, Coyne KS, Lundergan CF, Ross AM. Bedside monitoring of heparin therapy: comparison of activated clotting time to activated partial thromboplastin time. Cathet Cardiovasc Diagn 1994; 32:49-52.
4. Ten Boekel E, Bock M, Vrielink GJ, Liem R, Hendriks H, de Kieviet W. Detection of shortened activated partial thromboplastin times: an evaluation of different commercial reagents. Thromb Res 2007; 121:361-367.
5. Ten Boekel E, Bartels P. Abnormally short activated partial thromboplastin times are related to elevated plasma levels of TAT, F1+2, D-dimer and FVIII:C. Pathophysiol Haemost Thromb 2002; 32:137-142.
6. Tripodi A, Chantarangkul V, Martinelli I, Bucciarelli P, Mannucci PM. A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. Blood 2004; 104:3631-3634.
7. Legnani C, Mattarozzi S, Cini M, Cosmi B, Favaretto E, Palareti G. Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal. Br J Haematol 2006; 134:227-232.
8. Guirguis NG, Eicher C, Hock L, Lynch J, Graham VD, Rajagopalan PR, et al. Thromboembolic risk factors in patients undergoing kidney transplant: implication of abnormally short activated partial thromboplastin time. Ann Clin Lab Sci 2003; 33:396-400.
9. Guirguis N, Budisavljevic MN, Self S, Rajagopalan PR, Lazarchick J. Acute renal artery and vein thrombosis after renal transplant, associated with a short partial thromboplastin time and factor V Leiden mutation. Ann Clin Lab Sci 2000; 30:75-78.
10. Lippi G, Franchini M, Targher G, Montagnana M, Salvagno GL, Guidi GC, Favaloro EJ. Hyperthyroidism is associated with shortened APTT and increased fibrinogen values in a general population of unselected outpatients. J Thromb Thrombolysis 2009; 28:362-365.
11. Zwaal RF, Comfurius P, Bevers EM. Platelet procoagulant activity and microvesicle formation. Its putative role in hemostasis and thrombosis. Biochim Biophys Acta 1992; 1180:1-8.
12. Enjeti AK, Lincz LF, Seldon M. Detection and measurement of microparticles: an evolving research tool for vascular biology. Semin Thromb Hemost 2007; 33:771-779.
13. Enjeti AK, Lincz LF, Seldon M. Microparticles in health and disease. Semin Thromb Hemost 2008; 34:683-691.
14. Favaloro EJ. Towards a new paradigm for the identification and functional characterisation of von Willebrand disease. Semin Thromb Hemost 2009; 35:60-75.
15. Franchini M, Mannucci PM. Von Willebrand factor: another janus-faced hemostasis protein. Semin Thromb Hemost 2008; 34:663-669.
16. Favaloro EJ, Bonar R, Meiring M, Street A, Marsden K, on behalf of the RCPA QAP in Haematology. 2B or not 2B? Disparate discrimination of functionalVWF discordance using different assay panels or methodologies may lead to success or failure in the early identification of Type 2B VWD. Thromb Haemost 2007; 98:346-358.
17. Favaloro EJ, Grispo L, Exner T, Koutts J. Development of a simple collagen based ELISA assay aids in the diagnosis of, and permits sensitive discrimination between type I and type II, von Willebrand's disease. Blood Coagul Fibrinolysis 1991; 2:285-291.
18. Favaloro EJ. Collagen binding assay for von Willebrand factor (VWF:CBA): detection of von Willebrands Disease (VWD), and discrimination of VWD subtypes, depends on collagen source. Thromb Haemost 2000; 83:127-135.
19. Favaloro EJ, Soltani S, McDonald J, Grezchnik E, Easton L, Favaloro JW. Reassessment of ABO blood group, sex, and age on laboratory parameters used to diagnose von Willebrand disorder: potential influence on the diagnosis vs the potential association with risk of thrombosis. Am J Clin Pathol 2005; 124:910-917.
20. Exner T, Joseph J, Low J, Connor D, Ma D. A new activated factor X-based clotting method with improved specificity for procoagulant phospholipid. Blood Coagul Fibrinolysis 2003; 14:773-779.
21. Lippi G, Franchini M. Pathogenesis of venous thromboembolism: when the cup runneth over. Semin Thromb Hemost 2008; 34:747-761.
22. Stephan CL, SantaCruz K, May C, Wilkinson SB, Cunningham MT. Fatal dural sinus thrombosis associated with heterozygous factor V Leiden and a short activated partial thromboplastin time. Arch Pathol Lab Med 2003; 127:1359-1361.
23. van Dreden P, Rousseau A, Fontaine S, Woodhams BJ, Exner T. Clinical evaluation of a new functional test for detection of plasma procoagulant phospholipids. Blood Coagul Fibrinolysis 2009; 20:494-502.
24. Connor DE, Exner T, Ma DD, Joseph JE. Detection of the procoagulant activity of microparticle-associated phosphatidylserine using XACT. Blood Coagul Fibrinolysis 2009; 20:558-564.
25. Seo JW, Kim HK, Kim JE, Park S, Cho HI. Prognostic values of the factor Xa-activated clotting time and endogenous thrombin potential in patients suspected of having disseminated intravascular coagulation. Thromb Res 2009; 123:565-572.
26. Kilanowska J, Favaloro EJ, Lippi G. Aspirin 'responsiveness', 'nonresponsiveness' or 'resistance': a putative role for von Willebrand factor? Blood Coag Fibrinolysis 2008; 19:823-824.